# ImmuneOncia Therapeutics

Source: https://onco.cc/companies/immuneoncia-therapeutics/  
OnCo record `immuneoncia-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ImmuneOncia Therapeutics is a South Korea-based biotechnology company running 2 late-stage cancer trials of IMC-001 in peripheral T-cell lymphomas.

## Summary

ImmuneOncia Therapeutics, based in Yongin-si, South Korea, is a biotechnology company. ImmuneOncia Therapeutics develops immuno-oncology antibody drugs, stating its aim is to bring Korea's first immuno-oncology drug to market. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing IMC-001 in peripheral T-cell lymphomas. The largest, NCT06365840 (A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumour), plans to enrol 30 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: ImmuneOncia Therapeutics Inc.
- Tags: ctgov-sponsor
- HQ: Yongin-si
- Type: biotech
- Website: https://www.immuneoncia.com

## Sources

- Official website: https://www.immuneoncia.com
- ClinicalTrials.gov: trials led by ImmuneOncia Therapeutics: https://clinicaltrials.gov/search?lead=ImmuneOncia%20Therapeutics%20Inc.

## Connected records

- cancers: [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)
- trials: [A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor](https://onco.cc/trials/nct06365840/), [A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type](https://onco.cc/trials/nct04414163/)

---
JSON: https://onco.cc/api/v1/entities/immuneoncia-therapeutics.json